RBC Capital analyst Luca Issi lowered the firm’s price target on Dyne Therapeutics (DYN) to $23 from $25 and keeps an Outperform rating on the shares. The firm updated its model following the Q2 earnings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics: Promising Clinical Developments and Strategic Positioning Drive Buy Rating
- Dyne Therapeutics Advances in Neuromuscular Therapies
- Dyne Therapeutics reports Q2 EPS (97c), consensus (93c)
- Dyne Therapeutics expects cash to fund operations into Q3 of 2027
- Dyne Therapeutics CEO buys $911K in common stock